CTT-1057

Summary

Ctt-1057 (CHEMBL3427435) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including prostate adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 706.6 Da · C28H40FN4O14P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3427435
Name	CTT-1057
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	73386645
Molecular formula	C28H40FN4O14P
Molecular weight	706.6
InChIKey	IZLOSIXADNUSCM-ACRUOGEOSA-N

SMILES: C1=CC(=CC=C1C(=O)NCCCCCC(=O)N[C@@H](CCC(=O)N[C@@H](CCCOP(=O)(N[C@@H](CCC(=O)O)C(=O)O)O)C(=O)O)C(=O)O)F

IUPAC name: (2S)-2-[[[(4S)-4-carboxy-4-[[(4S)-4-carboxy-4-[6-[(4-fluorobenzoyl)amino]hexanoylamino]butanoyl]amino]butoxy]-hydroxyphosphoryl]amino]pentanedioic acid

Also known as: Ctt-1057, Ctt1057, CTT1057, CTT-1057

Parent form; salt/anhydrous children: CHEMBL5314445

Patent coverage: 13 distinct patent families (32 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Glutamate carboxypeptidase 2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FOLH1	6.4	IC50	400	nM	CHEMBL_ACT_15253404

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
prostate adenocarcinoma	3	MONDO:0005082	EFO:0000673

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02916537	PHASE1	COMPLETED	A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057
NCT03427476	PHASE1	COMPLETED	CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
NCT03822871	PHASE1	COMPLETED	A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).